Focuses on the Discovery of Novel Targets and
Development of Antibodies or Their Analogs
TG ImmunoPharma Established
Cooperation with Harbour BioMed on the Fully Human Antibody Platform H2L2
Awarded the Third Batch of Key Industrial Enterprises in Hefei, Anhui
Pre-Series A Financing Round lead by Casstar and Innoval Capital, other investors include Hefei Industry Investment Capital, Efung Capital, Tiantu Capital and Guoyuan Innovating Investment
Awarded the National Scientific and Technological Small and Medium-sized Enterprise
TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody
Awarded the VB-Find Award: the Top 100 most innovative medical technology products in the year of 2022
Hefei TG ImmunoPharma Co., Ltd.
Our location: #6 Intelligent Science and Technology Park, Jingkai District, Hefei, Anhui, China
Telephone: 0551-62861151
Email: contact@tgimmunopharma.com
ICP备字：皖ICP备2022011087号-1 （皖）-非经营性-2022-0075 皖公网安备 34019102001077号 ©Copyright by CSPC All rights reserved.
